London, UK, 24 March 2025: Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.
Closed Loop Medicine holds over 65 filings across 16 patent families, marking a significant milestone in its mission to deliver precision medicine at scale. The Company continues to expand its strong intellectual property foundation to safeguard the scalability of its innovations in personalized dosing, novel drug forms and drug-digital combination therapies.
In the rapidly-established GLP-1 market, Closed Loop Medicine has recognized the potential in delivering personalized solutions that address both the unpredictability of weight loss and the adverse effects that may otherwise limit patient adherence to weight management programs. The Company’s IP covers dose optimization according to patient-specific factors such as degree of calorie restriction or exercise, providing an opportunity for the development of personalized co-therapies enhancing existing GLP-1 medicines.
The latest patent granted by the US Patent Office extends Closed Loop Medicine’s cardiometabolic capabilities into DOAC therapy, enabling more personalized and effective anticoagulation treatment. This patent supports AI-powered precision dosing for patients requiring DOACs, improving safety and efficacy in stroke prevention and other cardiovascular conditions.
Dr. Hakim Yadi OBE, CEO and co-Founder of Closed Loop Medicine, says: “Establishing a strong and differentiated patent portfolio is central to our leadership in AI-enabled personalized medicine. These patents reinforce our ability to deliver smarter, AI-enabled pharmacometric dosing solutions. Not only to improve clinical outcomes and optimize treatment for cardiometabolic diseases with novel drug forms, but also software enhancements of existing drugs, the latter receiving timely support with the FDA’s recent Prescription Drug Use-Related SoftwarePDURS guidance”
For further information please contact:
Zyme Communications
Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Closed Loop Medicine
Dr. Hakim Yadi OBE, Chief Executive Officer
Email: info@closedloopmedicine.com
About Closed Loop Medicine
One size does not fit all when it comes to medicine.
Closed Loop Medicine is a TechBio company enhancing drug development through AI, machine learning, and personalized dosing, to bring forward the promise of precision care. The Company’s proprietary platform enhances treatment options by seamlessly integrating drugs and devices with patient-led digital experiences and closed-loop models of care – all under a single prescription. Working in combination with an expanding portfolio of new and established medicines, Closed Loop Medicine’s scalable approach to treating the individual, not just the disease, has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases.
Founded at the Babraham Institute in Cambridge, UK, and now based in London, UK, Closed Loop Medicine’s investors include Ananda Impact Ventures, BGF, LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels. The Company is supported by globally-renowned leaders across life sciences, healthcare, digital health, technology and regulatory sectors, including on its Board of Directors.
To learn more about Closed Loop Medicine and its mission to deliver precision care for all, please visit: www.closedloopmedicine.com
Follow Closed Loop Medicine on Twitter (@closed_loop_med) and LinkedIn (@Closed Loop Medicine)